122 results on '"Vanni, Irene"'
Search Results
2. Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer
- Author
-
Coco, Simona, Boccardo, Simona, Mora, Marco, Fontana, Vincenzo, Vanni, Irene, Genova, Carlo, Alama, Angela, Salvi, Sandra, Dal Bello, Maria Giovanna, Bonfiglio, Silvia, Rijavec, Erika, Sini, Claudio, Barletta, Giulia, Biello, Federica, Carli, Franca, Cavalieri, Zita, Burrafato, Giovanni, Longo, Luca, Ballestrero, Alberto, and Grossi, Francesco
- Published
- 2021
- Full Text
- View/download PDF
3. Chemical Diagnostics to Unveil Environments Enriched by First Stars.
- Author
-
Vanni, Irene, Salvadori, Stefania, D'Odorico, Valentina, Becker, George D., and Cupani, Guido
- Published
- 2024
- Full Text
- View/download PDF
4. Coping with formalin banning in pathology: under vacuum long-term tissue storage with no added formalin
- Author
-
Mastracci, Luca, Gambella, Alessandro, Bragoni, Alberto, Pigozzi, Simona, Pastorino, Lorenza, Vanni, Irene, Tosi, Ilaria, Campora, Michela, Fiocca, Roberto, and Grillo, Federica
- Published
- 2019
- Full Text
- View/download PDF
5. Understanding the checkpoint blockade in lung cancer immunotherapy
- Author
-
Dal Bello, Maria Giovanna, Alama, Angela, Coco, Simona, Vanni, Irene, and Grossi, Francesco
- Published
- 2017
- Full Text
- View/download PDF
6. Exosomes: a new horizon in lung cancer
- Author
-
Vanni, Irene, Alama, Angela, Grossi, Francesco, Dal Bello, Maria Giovanna, and Coco, Simona
- Published
- 2017
- Full Text
- View/download PDF
7. Germline POT1 Variants: A Critical Perspective on POT1 Tumor Predisposition Syndrome.
- Author
-
Andreotti, Virginia, Vanni, Irene, Pastorino, Lorenza, Ghiorzo, Paola, and Bruno, William
- Subjects
- *
CRITICAL analysis , *GERM cells , *SYNDROMES , *TUMORS ,CANCER susceptibility - Abstract
The Protection of Telomere 1 (POT1) gene was identified as a melanoma predisposition candidate nearly 10 years ago. Thereafter, various cancers have been proposed as associated with germline POT1 variants in the context of the so-called POT1 Predisposition Tumor Syndrome (POT1–TPD). While the key role, and related risks, of the alterations in POT1 in melanoma are established, the correlation between germline POT1 variants and the susceptibility to other cancers partially lacks evidence, due also to the rarity of POT1–TPD. Issues range from the absence of functional or segregation studies to biased datasets or the need for a revised classification of variants. Furthermore, a proposal of a surveillance protocol related to the cancers associated with POT1 pathogenic variants requires reliable data to avoid an excessive, possibly unjustified, burden for POT1 variant carriers. We propose a critical perspective regarding data published over the last 10 years that correlate POT1 variants to various types of cancer, other than cutaneous melanoma, to offer food for thought for the specialists who manage cancer predisposition syndromes and to stimulate a debate on the grey areas that have been exposed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Characterizing the true descendants of the first stars.
- Author
-
Vanni, Irene, Salvadori, Stefania, Skúladóttir, Ása, Rossi, Martina, and Koutsouridou, Ioanna
- Subjects
- *
GALACTIC halos , *STAR formation , *STELLAR populations , *PARAMETRIC modeling , *SUPERNOVAE , *PREDICTION models - Abstract
The metal-poor stars in the Galactic halo are thought to show the imprints of the first (Pop III) stars, and thus provide a glance at the first episodes of star formation. In this work, we aim at understanding whether all very metal-poor stars formed in environments polluted by Pop III supernovae (SNe) and at what level. With a general parametric model for early metal enrichment, we study the chemical abundances (from C to Zn) of an environment imprinted by a single Pop III SN. We investigate how these abundances depend on the initial mass and internal mixing of Pop III stars, as well as on their SN explosion energy. We then study how subsequent generations of normal (Pop II) SNe affect the Pop III chemical signatures. By comparing the observed chemical abundances with our model predictions, we show that stars with [C/Fe] > +2.5 form in environments polluted purely by low-energy Pop III SNe (E SN < 2 × 1051 erg). At lower [C/Fe], stars can be imprinted either by Pop III only, or also by normal Pop II SNe. The probability of being enriched by Pop II SNe increases as [C/Fe] decreases. When Pop II stars contribute more to the pollution, they wash out the diverse chemical peculiarities left by the different Pop III SNe, and the chemical dispersion between their descendants decreases. We conclude that C-normal stars (|$\rm [C/Fe] \le +0.7$|) have likely been enriched by Pop II SNe at a |$\ge 50~{{\ \rm per\ cent}}$| level and we identify in the abundance scatter a key diagnostic to pinpoint the signature of Pop III SNe. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
- Author
-
Dono, Mariella, De Luca, Giuseppa, Lastraioli, Sonia, Anselmi, Giorgia, Dal Bello, Maria Giovanna, Coco, Simona, Vanni, Irene, Grossi, Francesco, Vigani, Antonella, Genova, Carlo, Ferrarini, Manlio, Ravetti, Jean Louis, and Zupo, Simona
- Published
- 2019
- Full Text
- View/download PDF
10. Understanding the origin of CEMP – no stars through ultra-faint dwarfs.
- Author
-
Rossi, Martina, Salvadori, Stefania, Skúladóttir, Ása, and Vanni, Irene
- Subjects
ASYMPTOTIC giant branch stars ,MILKY Way ,STAR formation ,SUPERNOVAE ,DWARF galaxies ,GALACTIC evolution ,STELLAR populations - Abstract
The origin of Carbon Enhanced Metal-Poor (CEMP-no) stars with low abundances of neutron-capture elements is still unclear. These stars are ubiquitous, found primarily in the Milky Way halo and ultra-faint dwarf galaxies (UFDs). To make a major step forward, we developed a data-calibrated model for Böotes I that simultaneously includes all carbon sources: supernovae and asymptotic giant branch (AGB) stars both from first (Pop III) stars, and subsequent normal star formation (Pop II). We demonstrate that each of these sources leaves a specific chemical signature in the gas, allowing us to identify the origin of present day CEMP-no stars through their location in the A(C)–[Fe/H] diagram. The CEMP stars with A(C) > 6 are predominantly enriched by AGB Pop II stars. We identify a new class of moderate CEMP-s stars with A(C) ∼7 and 0 < [Ba/Fe] < + 1, imprinted by winds from AGB stars. True Pop III descendants are predicted to have A(C) < 6 and a constant [C/Mg] with [Fe/H], in perfect agreement with observations in Böotes I and the Milky Way halo. For the first time we now have a complete picture of the origins of CEMP-no stars which can and will be verified with future observations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients
- Author
-
Lamp, Merit, Origone, Paola, Geroldi, Alessandro, Verdiani, Simonetta, Gotta, Fabio, Caponnetto, Claudia, Devigili, Grazia, Verriello, Lorenzo, Scialò, Carlo, Cabona, Corrado, Canosa, Antonio, Vanni, Irene, Bellone, Emilia, Eleopra, Roberto, and Mandich, Paola
- Published
- 2018
- Full Text
- View/download PDF
12. Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting.
- Author
-
Vanni, Irene, Pastorino, Lorenza, Tanda, Enrica Teresa, Andreotti, Virginia, Dalmasso, Bruna, Solari, Nicola, Mascherini, Matteo, Cabiddu, Francesco, Guadagno, Antonio, Coco, Simona, Allavena, Eleonora, Bruno, William, Pietra, Gabriella, Croce, Michela, Gangemi, Rosaria, Piana, Michele, Zoppoli, Gabriele, Ferrando, Lorenzo, Spagnolo, Francesco, and Queirolo, Paola
- Subjects
- *
CELL-free DNA , *TREATMENT effectiveness , *GENETIC variation , *SEQUENCE analysis , *DNA copy number variations , *BRAF genes , *MELANOMA - Abstract
Although several studies have explored the molecular landscape of metastatic melanoma, the genetic determinants of therapy resistance are still largely unknown. Here, we aimed to determine the contribution of whole-exome sequencing and circulating free DNA (cfDNA) analysis in predicting response to therapy in a consecutive real-world cohort of 36 patients, undergoing fresh tissue biopsy and followed during treatment. Although the underpowered sample size limited statistical analysis, samples from non-responders had higher copy number variations and mutations in melanoma driver genes compared to responders in the BRAF V600+ subset. In the BRAF V600− subset, Tumor Mutational Burden (TMB) was twice that in responders vs. non-responders. Genomic layout revealed commonly known and novel potential intrinsic/acquired resistance driver gene variants. Among these, RAC1, FBXW7, GNAQ mutations, and BRAF/PTEN amplification/deletion were present in 42% and 67% of patients, respectively. Both Loss of Heterozygosity (LOH) load and tumor ploidy were inversely associated with TMB. In immunotherapy-treated patients, samples from responders showed higher TMB and lower LOH and were more frequently diploid compared to non-responders. Secondary germline testing and cfDNA analysis proved their efficacy in finding germline predisposing variants carriers (8.3%) and following dynamic changes during treatment as a surrogate of tissue biopsy, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Development and validation of a multiplex quantitative polymerase chain reaction assay for the detection of Mollicutes impurities in human cells, cultured under good manufacturing practice conditions, and following European Pharmacopoeia requirements and the International Conference on Harmonization guidelines
- Author
-
Vanni, Irene, Ugolotti, Elisabetta, Raso, Alessandro, Marco, Eddi Di, Melioli, Giovanni, and Biassoni, Roberto
- Published
- 2012
- Full Text
- View/download PDF
14. Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma.
- Author
-
Pastorino, Lorenza, Dalmasso, Bruna, Allavena, Eleonora, Vanni, Irene, Ugolini, Filippo, Baroni, Gianna, Croce, Michela, Guadagno, Antonio, Cabiddu, Francesco, Andreotti, Virginia, Bruno, William, Zoppoli, Gabriele, Ferrando, Lorenzo, Tanda, Enrica Teresa, Spagnolo, Francesco, Menin, Chiara, Gangemi, Rosaria, Massi, Daniela, and Ghiorzo, Paola
- Subjects
TUMOR suppressor genes ,HETEROZYGOSITY ,MELANOMA ,RNA sequencing - Abstract
ATM germline pathogenic variants were recently found enriched in high-risk melanoma patients. However, ATM loss of heterozygosity (LOH) has never been investigated in melanoma and, therefore, a causal association with melanoma development has not been established yet. The purpose of this study was to functionally characterize 13 germline ATM variants found in high-risk melanoma patients—and classified by in silico tools as pathogenic, uncertain significance, or benign—using multiple assays evaluating ATM/pATM expression and/or LOH in melanoma tissues and cell lines. We assessed ATM status by Immunohistochemistry (IHC), Western Blot, Whole-Exome Sequencing/Copy Number Variation analysis, and RNA sequencing, supported by Sanger sequencing and microsatellite analyses. For most variants, IHC results matched those obtained with in silico classification and LOH analysis. Two pathogenic variants (p.Ser1135_Lys1192del and p.Ser1993ArgfsTer23) showed LOH and complete loss of ATM activation in melanoma. Two variants of unknown significance (p.Asn358Ile and p.Asn796His) showed reduced expression and LOH, suggestive of a deleterious effect. This study, showing a classic two-hit scenario in a well-known tumor suppressor gene, supports the inclusion of melanoma in the ATM-related cancer spectrum. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma
- Author
-
Coco, Simona, Truini, Anna, Vanni, Irene, Genova, Carlo, Rosano, Camillo, Dal Bello, Maria Giovanna, Alama, Angela, Venè, Roberta, Rijavec, Erika, Barletta, Giulia, Biello, Federica, Boccardo, Francesco, and Grossi, Francesco
- Published
- 2015
- Full Text
- View/download PDF
16. Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients.
- Author
-
Puccini, Alberto, Ponzano, Marta, Dalmasso, Bruna, Vanni, Irene, Gandini, Annalice, Puglisi, Silvia, Borea, Roberto, Cremante, Malvina, Bruno, William, Andreotti, Virginia, Allavena, Eleonora, Martelli, Valentino, Catalano, Fabio, Grassi, Massimiliano, Iaia, Maria Laura, Pirrone, Chiara, Pastorino, Alessandro, Fornarini, Giuseppe, Sciallero, Stefania, and Ghiorzo, Paola
- Subjects
PANCREATIC tumors ,GENETIC mutation ,BRCA genes ,EARLY detection of cancer ,GENETIC testing ,GENETIC disorders ,HEALTH outcome assessment ,CANCER patients ,CANCER genes ,DISEASE susceptibility ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,LONGITUDINAL method ,HEREDITARY cancer syndromes - Published
- 2022
- Full Text
- View/download PDF
17. Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation
- Author
-
Mascelli, Samantha, Raso, Alessandro, Biassoni, Roberto, Severino, Mariasavina, Sak, Katrin, Joost, Kairit, Milanaccio, Claudia, Barra, Salvina, Grillo-Ruggieri, Filippo, Vanni, Irene, Consales, Alessandro, Cama, Armando, Capra, Valeria, Nozza, Paolo, and Garrè, Maria Luisa
- Published
- 2012
- Full Text
- View/download PDF
18. Troubleshooting fine-tuning procedures for qPCR system design
- Author
-
Raso, Alessandro, Mascelli, Samantha, Nozza, Paolo, Ugolotti, Elisabetta, Vanni, Irene, Capra, Valeria, and Biassoni, Roberto
- Published
- 2011
- Full Text
- View/download PDF
19. Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI).
- Author
-
Vanni, Irene, Casula, Milena, Pastorino, Lorenza, Manca, Antonella, Dalmasso, Bruna, Andreotti, Virginia, Pisano, Marina, Colombino, Maria, Italian Association for Cancer Research (AIRC) Study Group, Covre, Alessia, Di Giacomo, Anna Maria, Maio, Michele, De Logu, Francesco, Massi, Daniela, Portelli, Francesca, Anichini, Andrea, Mortarini, Roberta, Bruno, William, Cabiddu, Francesco, and Spagnolo, Francesco
- Subjects
- *
NUCLEOTIDE sequencing , *MELANOMA , *BRAF genes , *SOMATIC mutation , *GENE frequency , *DETECTION limit - Abstract
Background: Identification of somatic mutations in key oncogenes in melanoma is important to lead the effective and efficient use of personalized anticancer treatment. Conventional methods focus on few genes per run and, therefore, are unable to screen for multiple genes simultaneously. The use of Next-Generation Sequencing (NGS) technologies enables sequencing of multiple cancer-driving genes in a single assay, with reduced costs and DNA quantity needed and increased mutation detection sensitivity. Methods: We designed a customized IMI somatic gene panel for targeted sequencing of actionable melanoma mutations; this panel was tested on three different NGS platforms using 11 metastatic melanoma tissue samples in blinded manner between two EMQN quality certificated laboratory. Results: The detection limit of our assay was set-up to a Variant Allele Frequency (VAF) of 10% with a coverage of at least 200x. All somatic variants detected by all NGS platforms with a VAF ≥ 10%, were also validated by an independent method. The IMI panel achieved a very good concordance among the three NGS platforms. Conclusion: This study demonstrated that, using the main sequencing platforms currently available in the diagnostic setting, the IMI panel can be adopted among different centers providing comparable results. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
- Author
-
Ottonello, Selene, Genova, Carlo, Cossu, Irene, Fontana, Vincenzo, Rijavec, Erika, Rossi, Giovanni, Biello, Federica, Dal Bello, Maria Giovanna, Tagliamento, Marco, Alama, Angela, Coco, Simona, Boccardo, Simona, Vanni, Irene, Ferlazzo, Guido, Moretta, Lorenzo, Grossi, Francesco, Mingari, Maria Cristina, Carrega, Paolo, and Pietra, Gabriella
- Subjects
NON-small-cell lung carcinoma ,LYMPHOCYTE subsets ,KILLER cells ,T cells - Abstract
Immune checkpoint blockade represents a major breakthrough in advanced non-small cell lung cancer (NSCLC) therapy. However, success is limited to a subset of patients and there is a critical need to identify robust biomarkers associated with clinical response. In this study, we assessed whether pre-existing immunological characteristics, as well as immune parameters measured during treatment, might provide such clinical guidance. We studied blood samples collected at baseline and during treatment in a cohort of advanced NSCLC patients (n = 74) treated with nivolumab. Several lymphocyte subsets and biomarkers were then correlated with overall survival (OS) as well as clinical response, assessed using RECIST criteria. We found that patients characterized by longer OS had higher levels of CD3
+ , CD4+ , and CD8+ T cells but lower levels of NK cells at baseline. Moreover, that they displayed a statistically significant lower expression of PD-1 on both CD3+ and CD8+ T cells (p = 0.013 and p = 0.033, respectively). The pre-treatment level of exhausted T cells (CD8+ PD1+ Eomes+ ) was significantly lower in patients with controlled disease (CD), defined as partial response (PR), and stable disease (SD), compared to those with progressive disease (PD) (p = 0.046). In CD patients, the frequency of exhausted CD8+ T cells further decreased during treatment cycles (p = <0.0001, p = 0.0032, and p = 0.0239, respectively). In conclusion, our results suggest that the distribution of lymphocyte subsets and expression of PD-1 on T cells before treatment may help predict the outcome of anti-PD-1 treatment in NSCLC patients. In addition, assessing the initial levels of exhausted T cells as well as their decrease upon treatment may also predict response and clinical outcome. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
21. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: 18F-FDG PET/CT Study.
- Author
-
Morbelli, Silvia, Alama, Angela, Ferrarazzo, Giulia, Coco, Simona, Genova, Carlo, Rijavec, Erika, Bongioanni, Francesca, Biello, Federica, Dal Bello, Maria Giovanna, Barletta, Giulia, Massollo, Michela, Vanni, Irene, Piva, Roberta, Nieri, Alberto, Bauckneht, Matteo, Sambuceti, Gianmario, and Grossi, Francesco
- Published
- 2017
- Full Text
- View/download PDF
22. P3.02c-072 Predictive Immunologic Markers of Response to Nivolumab in Non-Small Cell Lung Cancer: Topic: IT Biomarkers
- Author
-
Genova, Carlo, Carrega, Paolo, Distefano, Roberta, Ottonello, Selene, Pietra, Gabriella, Cossu, Irene, Rijavec, Erika, Biello, Federica, Rossi, Giovanni, Barletta, Giulia, Dal Bello, Maria Giovanna, Alama, Angela, Coco, Simona, Vanni, Irene, Maggioni, Claudia, Merlo, Franco, Mingari, Maria Cristina, and Grossi, Francesco
- Published
- 2017
- Full Text
- View/download PDF
23. P3.02c-054 Prognostic Role of cfDNA in Patients with NSCLC under Treatment with Nivolumab: Topic: IT
- Author
-
Biello, Federica, Alama, Angela, Dal Bello, Maria Giovanna, Coco, Simona, Vanni, Irene, Rijavec, Erika, Genova, Carlo, Barletta, Giulia, Rossi, Giovanni, Maggioni, Claudia, Diaz Gaitan, Nidia Sofia, Distefano, Roberta, Merlo, Franco, and Grossi, Francesco
- Published
- 2017
- Full Text
- View/download PDF
24. P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy
- Author
-
Dal Bello, Maria Giovanna, Filiberti, Rosangela, Rijavec, Erka, Genova, Carlo, Barletta, Giulia, Rossi, Giovanni, Biello, Federica, Distefano, Roberta, Orengo, Anna Maria, Alama, Angela, Coco, Simona, Vanni, Irene, Mussap, Michele, and Grossi, Francesco
- Published
- 2017
- Full Text
- View/download PDF
25. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
- Author
-
Coco, Simona, Alama, Angela, Vanni, Irene, Fontana, Vincenzo, Genova, Carlo, Dal Bello, Maria Giovanna, Truini, Anna, Rijavec, Erika, Biello, Federica, Sini, Claudio, Burrafato, Giovanni, Maggioni, Claudia, Barletta, Giulia, and Grossi, Francesco
- Subjects
CIRCULATING tumor DNA ,LUNG cancer ,CANCER chemotherapy ,BIOMARKERS ,PROGNOSTIC tests - Abstract
Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are promising prognostic and predictive biomarkers in non-small cell lung cancer (NSCLC). In this study, we examined the prognostic role of cfDNA and CTCs, in separate and joint analyses, in NSCLC patients receiving first line chemotherapy. Seventy-three patients with advanced NSCLC were enrolled in this study. CfDNA and CTC were analyzed at baseline and after two cycles of chemotherapy. Plasma cfDNA quantification was performed by quantitative PCR (qPCR) whereas CTCs were isolated by the ScreenCell Cyto (ScreenCell, Paris, France) device and enumerated according to malignant features. Patients with baseline cfDNA higher than the median value (96.3 hTERT copy number) had a significantly worse overall survival (OS) and double the risk of death (hazard ratio (HR): 2.14; 95% confidence limits (CL) = 1.24–3.68; p-value = 0.006). Conversely, an inverse relationship between CTC median baseline number (6 CTC/3 mL of blood) and OS was observed. In addition, we found that in patients reporting stable disease (SD), the baseline cfDNA and CTCs were able to discriminate patients at high risk of poor survival. cfDNA demonstrated a more reliable biomarker than CTCs in the overall population. In the subgroup of SD patients, both biomarkers identified patients at high risk of poor prognosis who might deserve additional/alternative therapeutic interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma.
- Author
-
Vanni, Irene, Coco, Simona, Bonfiglio, Silvia, Cittaro, Davide, Genova, Carlo, Biello, Federica, Mora, Marco, Rossella, Valeria, Dal Bello, Maria Giovanna, Truini, Anna, Banelli, Barbara, Lazarevic, Dejan, Alama, Angela, Rijavec, Erika, Barletta, Giulia, and Grossi, Francesco
- Published
- 2016
- Full Text
- View/download PDF
27. Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.
- Author
-
Bonfiglio, Silvia, Vanni, Irene, Rossella, Valeria, Truini, Anna, Lazarevic, Dejan, Dal Bello, Maria Giovanna, Alama, Angela, Mora, Marco, Rijavec, Erika, Genova, Carlo, Cittaro, Davide, Grossi, Francesco, and Coco, Simona
- Subjects
- *
EXOMES , *ADENOCARCINOMA , *PHYSIOLOGICAL effects of formaldehyde , *GENOMES , *CANCER genetics , *CANCER invasiveness , *DNA analysis , *COMPARATIVE studies , *DIAGNOSTIC reagents & test kits , *TISSUE fixation (Histology) , *FORMALDEHYDE , *HISTOLOGICAL techniques , *LUNG tumors , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *EVALUATION research , *GENE expression profiling , *SEQUENCE analysis - Abstract
Background: Next Generation Sequencing (NGS) has become a valuable tool for molecular landscape characterization of cancer genomes, leading to a better understanding of tumor onset and progression, and opening new avenues in translational oncology. Formalin-fixed paraffin-embedded (FFPE) tissue is the method of choice for storage of clinical samples, however low quality of FFPE genomic DNA (gDNA) can limit its use for downstream applications.Methods: To investigate the FFPE specimen suitability for NGS analysis and to establish the performance of two solution-based exome capture technologies, we compared the whole-exome sequencing (WES) data of gDNA extracted from 5 fresh frozen (FF) and 5 matched FFPE lung adenocarcinoma tissues using: SeqCap EZ Human Exome v.3.0 (Roche NimbleGen) and SureSelect XT Human All Exon v.5 (Agilent Technologies).Results: Sequencing metrics on Illumina HiSeq were optimal for both exome systems and comparable among FFPE and FF samples, with a slight increase of PCR duplicates in FFPE, mainly in Roche NimbleGen libraries. Comparison of single nucleotide variants (SNVs) between FFPE-FF pairs reached overlapping values >90 % in both systems. Both WES showed high concordance with target re-sequencing data by Ion PGM™ in 22 lung-cancer genes, regardless the source of samples. Exon coverage of 623 cancer-related genes revealed high coverage efficiency of both kits, proposing WES as a valid alternative to target re-sequencing.Conclusions: High-quality and reliable data can be successfully obtained from WES of FFPE samples starting from a relatively low amount of input gDNA, suggesting the inclusion of NGS-based tests into clinical contest. In conclusion, our analysis suggests that the WES approach could be extended to a translational research context as well as to the clinic (e.g. to study rare malignancies), where the simultaneous analysis of the whole coding region of the genome may help in the detection of cancer-linked variants. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
28. Next-Generation SequencingWorkflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.
- Author
-
Vanni, Irene, Coco, Simona, Truini, Anna, Rusmini, Marta, Dal Bello, Maria Giovanna, Alama, Angela, Banelli, Barbara, Mora, Marco, Rijavec, Erika, Barletta, Giulia, Genova, Carlo, Biello, Federica, Maggioni, Claudia, and Grossi, Francesco
- Subjects
- *
NUCLEOTIDE sequencing , *COST effectiveness , *IONS , *SINGLE nucleotide polymorphisms , *QUALITY control - Abstract
Next-generation sequencing (NGS) is a cost-effective technology capable of screening several genes simultaneously; however, its application in a clinical context requires an established workflow to acquire reliable sequencing results. Here, we report an optimized NGS workflow analyzing 22 lung cancer-related genes to sequence critical samples such as DNA from formalin-fixed paraffin-embedded (FFPE) blocks and circulating free DNA (cfDNA). Snap frozen and matched FFPE gDNA from 12 non-small cell lung cancer (NSCLC) patients, whose gDNA fragmentation status was previously evaluated using a multiplex PCR-based quality control, were successfully sequenced with Ion Torrent PGM™. The robust bioinformatic pipeline allowed us to correctly call both Single Nucleotide Variants (SNVs) and indels with a detection limit of 5%, achieving 100% specificity and 96% sensitivity. This workflow was also validated in 13 FFPE NSCLC biopsies. Furthermore, a specific protocol for low input gDNA capable of producing good sequencing data with high coverage, high uniformity, and a low error rate was also optimized. In conclusion, we demonstrate the feasibility of obtaining gDNA from FFPE samples suitable for NGS by performing appropriate quality controls. The optimized workflow, capable of screening low input gDNA, highlights NGS as a potential tool in the detection, disease monitoring, and treatment of NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
29. Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms.
- Author
-
Moroni, Marco, Ghezzi, Silvia, Baroli, Paolo, Heltai, Silvia, Battista, Davide De, Pensieroso, Simone, Cavarelli, Mariangela, Dispinseri, Stefania, Vanni, Irene, Pastori, Claudia, Zerbi, Pietro, Tosoni, Antonella, Vicenzi, Elisa, Nebuloni, Manuela, Kim Wong, Hong Zhao, McHugh, Sarah, Poli, Guido, Lopalco, Lucia, and Scarlatti, Gabriella
- Subjects
VIREMIA ,GENETIC polymorphisms ,VIROLOGY ,DISEASE susceptibility ,ANTIRETROVIRAL agents ,T cells ,ALLELES ,THERAPEUTICS - Abstract
Introduction Understanding the mechanisms by which some individuals are able to naturally control HIV- 1 infection is an important goal of AIDS research. We here describe the case of an HIV-1
+ woman, CASE1, who has spontaneously controlled her viremia for the last 14 of her 20 years of infection. Methods CASE1 has been clinically monitored since 1993. Detailed immunological, virological and histological analyses were performed on samples obtained between 2009 and 2011. Results As for other Elite Controllers, CASE1 is characterized by low to undetectable levels of plasma HIV-1 RNA, peripheral blood mononuclear cell (PBMC) associated HIV-1 DNA a reduced in vitro susceptibility of target cells to HIV-1 infection. Furthermore, a slow rate of virus evolution was demonstrated in spite the lack of assumption of any antiretroviral agent. CASE1 failed to transmit HIV-1 to either her sexual male partner or to her child born by vaginal delivery. Normal values and ratios of T and B cells were observed, along with normal histology of the intestinal mucosa. Attempts to isolate HIV-1 from her PBMC and gut-derived cells were unsuccessful, despite expression of normal cell surface levels of CD4, CCRC5 and CXCR4. CASE1 did not produce detectable anti-HIV neutralizing antibodies in her serum or genital mucosal fluid although she displayed potent T cell responses against HIV-1 Gag and Nef. CASE1 also possessed multiple genetic polymorphisms, including HLA alleles (B*14, B*57, C*06 and C*08.02) and HLA-C single nucleotide polymorphisms (SNPs, rs9264942 C/C and rs67384697 del/del), that have been previously individually associated with spontaneous control of plasma viremia, maintenance of high CD4+ T cell counts and delayed disease progression Conclusions CASE1 has controlled her HIV-1 viremia below the limit of detection in the absence of antiretroviral therapy for more than 14 years and has not shown any sign of immunologic deterioration or disease progression. Co-expression of multiple protective HLA alleles, HLA-C SNPs and strong T cell responses against HIV-1 proteins are the most likely explanation of this very benign case of spontaneous control of HIV-1 disease progression. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
30. Clinical applications of circulating tumor cells in lung cancer patients by CellSearch system.
- Author
-
Truini, Anna, Alama, Angela, Dal Bello, Maria Giovanna, Coco, Simona, Vanni, Irene, Rijavec, Erika, Genova, Carlo, Barletta, Giulia, Biello, Federica, and Grossi, Francesco
- Subjects
LUNG cancer patients ,LUNG cancer diagnosis ,BREAST cancer ,PROSTATE cancer ,LUNG cancer prognosis - Abstract
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that might represent an important biomarker in lung cancer. The prognosis of patients diagnosed with lung cancer is generally poor mainly due to late diagnosis. Recent evidences have reported that tumor aggressiveness is associated with the presence of CTCs in the blood stream; therefore, several studies have focused their attention on CTC isolation, characterization, and clinical significance. So far, the CellSearch
® system is the only approach approved by FDA for metastatic breast, prostate, and colorectal cancer intended to detect CTCs of epithelial origin in whole blood and to assess prognosis. To date, no specific biomarkers have been validated in lung cancer and the identification of novel tumor markers such as CTCs might highly contribute to lung cancer prognosis and management. In the present review, the significance of CTC detection in lung cancer is examined through the analysis of the published studies in both non-small cell and small cell lung cancers; additionally the prognostic and the clinical role of CTC enumeration in treatment monitoring will be reported and discussed. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
31. Detection of ganciclovir resistance mutations by pyrosequencing in HCMV-infected pediatric patients
- Author
-
Benzi, Fabio, Vanni, Irene, Cassina, Giulia, Ugolotti, Elisabetta, Di Marco, Eddi, Cirillo, Carmela, Cristina, Emilio, Morreale, Giuseppe, Melioli, Giovanni, Malnati, Mauro, and Biassoni, Roberto
- Subjects
- *
GANCICLOVIR , *GENETIC mutation , *HUMAN cytomegalovirus , *PATHOGENIC microorganisms , *ANTIVIRAL agents , *PHENOTYPES , *PROTEIN kinases , *PEDIATRICS - Abstract
Abstract: Background: Human cytomegalovirus (HCMV) is an opportunistic pathogen especially for immuno-suppressed subjects that might develop pharmacological resistance in patients undergoing prolonged antiviral treatment. Ganciclovir (GCV) is the drug used as first choice therapy in affected children and a GCV-resistant phenotype is mainly linked to mutations of the viral protein kinase UL97. Objectives: Here a new quantitative pyrosequence (PSQ) method is presented that allows detection and quantification of the viral species carrying the more frequent UL97 mutations responsible for GCV resistance in clinical samples (>80% of known cases). Study design: The system has been validated using two independent approaches (cloning and sequencing of UL-97 gene fragments and real-time PCR) and clinical samples derived from 3 pediatric patients. Results: The UL97 pyrosequencing analysis has indicated a significant increase of mutant viruses carrying the H520Q and C592G mutations. In particular, the H520Q viral mutation, known to increase GCV resistance (IC50=10) increased around 5 times during hospitalization. In addition, C592G (known to have IC50=2.9) also increased 3 times. Conclusions: PSQ is a quick, cheap, high throughput and sensitive analysis method to detect GCV-associated resistance mutation useful to follow antiviral therapy in perinatal CMV-infection as well as in immune-suppressed patients. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
32. Human leukocyte antigen–B (-Bw6/-Bw4 I80, T80) and human leukocyte antigen–C (-C1/-C2) subgrouping using pyrosequence analysis
- Author
-
Ugolotti, Elisabetta, Vanni, Irene, Raso, Alessandro, Benzi, Fabio, Malnati, Mauro, and Biassoni, Roberto
- Subjects
- *
HLA histocompatibility antigens , *IMMUNOGLOBULINS , *T cells , *GENES , *IMMUNOGLOBULIN allotypes , *EPITOPES , *KILLER cells , *AMINO acids , *AUTOIMMUNE diseases , *CANCER - Abstract
Abstract: Specific combinations of killer immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA) class I molecules characterized by a particular residue 80 are significantly associated with outcomes in different pathologic conditions, such as autoimmunity, pathogenic infection, cancer, and reproductive failure. Thus, a simplified method for HLA typing used in association with the analysis of KIR genotype (Kirotype) is of particular interest to extend the analysis of larger series. Here, we describe a quick and inexpensive method that allows use of pyrosequencing, a helpful subtyping of HLA class I molecules, into HLA-Bw6, -Bw4 I80 or -Bw4 T80, HLA-C1, or -C2 groups and HLA-A allotypes sharing Bw4+ epitope or the rare HLA-B allotypes displaying the C1 motif. In particular, this analysis is focused on the amino acids around residue 80, known to be relevant in defining the affinity of KIR/HLA interaction and in the functional effects. This method was demonstrated to have good sensitivity, specificity, and reproducibility of detection and it was validated using a panel of HLA-typed International Histocompatibility Workshop (IHW) cell lines and clinical isolates. Using an allele quantitative acquisition mode, the method permitted us to obtain an accurate sequencing as required in heterozygous and/or homozygous sample definition. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
33. Relationship between the miRNA Profiles and Oncogene Mutations in Non-Smoker Lung Cancer. Relevance for Lung Cancer Personalized Screenings and Treatments.
- Author
-
Izzotti, Alberto, Coronel Vargas, Gabriela, Pulliero, Alessandra, Coco, Simona, Vanni, Irene, Colarossi, Cristina, Blanco, Giuseppina, Agodi, Antonella, Barchitta, Martina, Maugeri, Andrea, Oliveri Conti, Gea, Ferrante, Margherita, Sciacca, Salvatore, and Bertagnolo, Valeria
- Subjects
LUNG cancer ,MICRORNA ,EARLY detection of cancer ,BLOOD plasma ,CANCER patients - Abstract
Oncogene mutations may be drivers of the carcinogenesis process. MicroRNA (miRNA) alterations may be adaptive or pathogenic and can have consequences only when mutation in the controlled oncogenes occurs. The aim of this research was to analyze the interplay between miRNA expression and oncogene mutation. A total of 2549 miRNAs were analyzed in cancer tissue—in surrounding normal lung tissue collected from 64 non-smoking patients and in blood plasma. Mutations in 92 hotspots of 22 oncogenes were tested in the lung cancer tissue. MicroRNA alterations were related to the mutations occurring in cancer patients. Conversely, the frequency of mutation occurrence was variable and spanned from the k-ras and p53 mutation detected in 30% of patients to 20% of patients in which no mutation was detected. The prediction of survival at a 3-year follow up did not occur for mutation analysis but was, conversely, well evident for miRNA analysis highlighting a pattern of miRNA distinguishing between survivors and death in patients 3 years before this clinical onset. A signature of six lung cancer specific miRNAs occurring both in the lungs and blood was identified. The obtained results provide evidence that the analysis of both miRNA and oncogene mutations was more informative than the oncogene mutation analysis currently performed in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1.
- Author
-
Pastorino, Lorenza, Andreotti, Virginia, Dalmasso, Bruna, Vanni, Irene, Ciccarese, Giulia, Mandalà, Mario, Spadola, Giuseppe, Pizzichetta, Maria Antonietta, Ponti, Giovanni, Tibiletti, Maria Grazia, Sala, Elena, Genuardi, Maurizio, Chiurazzi, Pietro, Maccanti, Gabriele, Manoukian, Siranoush, Sestini, Serena, Danesi, Rita, Zampiga, Valentina, La Starza, Roberta, and Stanganelli, Ignazio
- Subjects
GENETIC techniques ,MELANOMA ,GENETIC mutation ,TUMOR markers ,DISEASE risk factors - Abstract
The contribution of recently established or candidate susceptibility genes to melanoma missing heritability has yet to be determined. Multigene panel testing could increase diagnostic yield and better define the role of candidate genes. We characterized 273 CDKN2A/ARF and CDK4-negative probands through a custom-designed targeted gene panel that included CDKN2A/ARF, CDK4, ACD, BAP1, MITF, POT1, TERF2IP, ATM, and PALB2. Co-segregation, loss of heterozygosity (LOH)/protein expression analysis, and splicing characterization were performed to improve variant classification. We identified 16 (5.9%) pathogenic and likely pathogenic variants in established high/medium penetrance cutaneous melanoma susceptibility genes (BAP1, POT1, ACD, MITF, and TERF2IP), including two novel variants in BAP1 and 4 in POT1. We also found four deleterious and five likely deleterious variants in ATM (3.3%). Thus, including potentially deleterious variants in ATM increased the diagnostic yield to about 9%. Inclusion of rare variants of uncertain significance would increase the overall detection yield to 14%. At least 10% of melanoma missing heritability may be explained through panel testing in our population. To our knowledge, this is the highest frequency of putative ATM deleterious variants reported in melanoma families, suggesting a possible role in melanoma susceptibility, which needs further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
- Author
-
Alama, Angela, Simona Coco, Vanni, Irene, and Grossi, Francesco
- Subjects
CANCER chemotherapy ,TUMORS ,LUNG cancer - Published
- 2017
- Full Text
- View/download PDF
36. Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
- Author
-
Genova, Carlo, Boccardo, Simona, Mora, Marco, Rijavec, Erika, Biello, Federica, Rossi, Giovanni, Tagliamento, Marco, Dal Bello, Maria Giovanna, Coco, Simona, Alama, Angela, Vanni, Irene, Barletta, Giulia, Bianchi, Rita, Maggioni, Claudia, Bruzzi, Paolo, and Grossi, Francesco
- Subjects
NON-small-cell lung carcinoma ,CANCER patients ,PROGRESSION-free survival ,UNIVARIATE analysis ,MULTIVARIATE analysis - Abstract
Reliable predictors of benefit from immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are still limited. We aimed to evaluate the association between the expression of selected molecules involved in immune response and clinical outcomes in NSCLC patients receiving nivolumab. In our study, the outcomes of 46 NSCLC patients treated with nivolumab in second or subsequent lines (Nivolumab Cohort) were compared with the expression of PD-L1, PD-L2, PD-1, B7-H3, and B7-H4 assessed by immunohistochemistry (IHC). Samples from 17 patients (37.0%) in the Nivolumab Cohort were positive for B7-H4 expression. At univariate analyses, only B7-H4 expression was associated with significantly decreased progression-free survival (PFS; 1.7 vs. 2.0 months; p = 0.026) and with a disadvantage in terms of overall survival (OS) close to statistical significance (4.4 vs. 9.8 months; p = 0.064). At multivariate analyses, B7-H4 expression was significantly associated with decreased PFS (hazard ratio (HR) = 2.28; p = 0.021) and OS (HR = 2.38; p = 0.022). Subsequently, B7-H4 expression was compared with clinical outcomes of 27 NSCLC patients receiving platinum-based chemotherapy (Chemotherapy Cohort), but no significant association was observed. Our results suggest a negative predictive role of B7-H4 in a population of NSCLC treated with immune checkpoint inhibitors, which deserves further research. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer.
- Author
-
Coco, Simona, Bonfiglio, Silvia, Cittaro, Davide, Vanni, Irene, Mora, Marco, Genova, Carlo, Dal Bello, Maria Giovanna, Boccardo, Simona, Alama, Angela, Rijavec, Erika, Sini, Claudio, Rossella, Valeria, Barletta, Giulia, Biello, Federica, Truini, Anna, Bruzzo, Cristina, Gallo, Maurizio, Lazarevic, Dejan, Ballestrero, Alberto, and Grossi, Francesco
- Subjects
LUNG tumors ,ALLELES ,BREAST tumors ,DISEASE susceptibility ,GENES ,GERM cells ,GENETIC mutation ,WOMEN'S health ,SEQUENCE analysis ,DISEASE complications ,GENETICS ,TUMOR risk factors - Abstract
Women treated for breast cancer (BC) are at risk of developing secondary tumors, such as lung cancer (LC). Since rare germline variants have been linked to multiple cancer development, we hypothesized that BC survivors might be prone to develop LC as a result of harboring rare variants. Sixty patients with LC with previous BC (the study population; SP) and 53 women with either BC or LC and no secondary cancer (control population; CP) were enrolled. Whole exome sequencing was performed in both tumors and unaffected tissues from 28/60 SP patients, and in germline DNA from 32/53 CP. Candidate genes were validated in the remaining individuals from both populations. We found two main mutational signature profiles: S1 (C>T) in all BCs and 16/28 LCs, and S2 (C>A) which is strongly associated with smoking, in 12/28 LCs. The burden test over rare germline variants in S1-LC vs CP identified 248 genes. Validation confirmed GSN as significantly associated with LC in never-smokers. In conclusion, our data suggest two signatures involved in LC onset in women with previous BC. One of these signatures is linked to smoking. Conversely, regardless of smoking habit, in a subgroup of BC survivors genetic susceptibility may contribute to LC risk. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control.
- Author
-
Malnati, Mauro S., Ugolotti, Elisabetta, Monti, Maria Cristina, Battista, Davide De, Vanni, Irene, Bordo, Domenico, Sironi, Francesca, Larghero, Patrizia, Marco, Eddi Di, Biswas, Priscilla, Poli, Guido, Vicenzi, Elisa, Riva, Agostino, Tarkowski, Maciej, Tambussi, Giuseppe, Nozza, Silvia, Tripodi, Gino, Marras, Francesco, Maria, Andrea De, and Pistorio, Angela
- Abstract
Several studies demonstrated a relevant role of polymorphisms located within the HLA-B and -C loci and the Killer Immunoglobulin Receptors (KIRs) 3DL1 and 3DS1 in controlling HIV-1 replication. KIRs are regulatory receptors expressed at the surface of NK and CD8+ T-cells that specifically bind HLA-A and -B alleles belonging to the Bw4 supratype and all the -C alleles expressing the C1 or C2 supratype. We here disclose a novel signature associated with the Elite Controller but not with the long-term nonprogressor status concerning 2DS activating KIRs and HLA-C2 alleles insensitive to miRNA148a regulation. Overall, our findings support a crucial role of NK cells in the control of HIV-1 viremia. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Molecular characterization of hospital-acquired methicillin-resistant Staphylococcus aureus strains in pediatric outbreaks using variable tandem repeat analysis with spa and ClfB typing
- Author
-
Ugolotti, Elisabetta, Bandettini, Roberto, Marchese, Anna, Gualco, Laura, Vanni, Irene, Borzi, Luana, Di Marco, Eddi, Castagnola, Elio, Melioli, Giovanni, and Biassoni, Roberto
- Subjects
- *
METHICILLIN resistance , *MOLECULAR biology , *STAPHYLOCOCCUS aureus , *PEDIATRICS , *DISEASE outbreaks , *CHILDREN'S hospitals , *NUCLEOTIDE sequence , *GENE targeting , *GENETIC polymorphisms - Abstract
Abstract: To analyze 67 clinical methicillin-resistant Staphylococcus aureus (MRSA) isolated from pediatric hospital infections, we used multilocus variable-number tandem-repeat DNA sequence-based techniques, targeting the protein A polymorphic X region and the clumping factor B complete R domain. We define a “clfB similarity score” and then compare the double loci analysis of closely related MRSA isolates with pulsed-field gel electrophoresis (PFGE). We found an endemic clone (MLST-ST8, spa-t008, SCCmecIV, ClfB lineage 1) able to originate 3 possible outbreaks and a second clone (MLST-ST152, spa-t355, SCCmecV, ClfB lineage 4) responsible for limited cases of MRSA infections, indicating that the combination of spa and clfB-lineage typing is useful to trace MRSA pediatric outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
40. Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.
- Author
-
Vanni I, Tanda ET, Dalmasso B, Pastorino L, Andreotti V, Bruno W, Boutros A, Spagnolo F, and Ghiorzo P
- Abstract
Melanoma is one of the most aggressive tumors of the skin, and its incidence is growing worldwide. Historically considered a drug resistant disease, since 2011 the therapeutic landscape of melanoma has radically changed. Indeed, the improved knowledge of the immune system and its interactions with the tumor, and the ever more thorough molecular characterization of the disease, has allowed the development of immunotherapy on the one hand, and molecular target therapies on the other. The increased availability of more performing technologies like Next-Generation Sequencing (NGS), and the availability of increasingly large genetic panels, allows the identification of several potential therapeutic targets. In light of this, numerous clinical and preclinical trials are ongoing, to identify new molecular targets. Here, we review the landscape of mutated non- BRAF skin melanoma, in light of recent data deriving from Whole-Exome Sequencing (WES) or Whole-Genome Sequencing (WGS) studies on melanoma cohorts for which information on the mutation rate of each gene was available, for a total of 10 NGS studies and 992 samples, focusing on available, or in experimentation, targeted therapies beyond those targeting mutated BRAF. Namely, we describe 33 established and candidate driver genes altered with frequency greater than 1.5%, and the current status of targeted therapy for each gene. Only 1.1% of the samples showed no coding mutations, whereas 30% showed at least one mutation in the RAS genes (mostly NRAS ) and 70% showed mutations outside of the RAS genes, suggesting potential new roads for targeted therapy. Ongoing clinical trials are available for 33.3% of the most frequently altered genes., (Copyright © 2020 Vanni, Tanda, Dalmasso, Pastorino, Andreotti, Bruno, Boutros, Spagnolo and Ghiorzo.)
- Published
- 2020
- Full Text
- View/download PDF
41. Current State of Target Treatment in BRAF Mutated Melanoma.
- Author
-
Tanda ET, Vanni I, Boutros A, Andreotti V, Bruno W, Ghiorzo P, and Spagnolo F
- Abstract
Incidence of melanoma has been constantly growing during the last decades. Although most of the new diagnoses are represented by thin melanomas, the number of melanoma-related deaths in 2018 was 60,712 worldwide (Global Cancer Observatory, 2019). Until 2011, no systemic therapy showed to improve survival in patients with advanced or metastatic melanoma. At that time, standard of care was chemotherapy, with very limited results. The identification of BRAF V600 mutation, and the subsequent introduction of BRAF targeting drugs, radically changed the clinical practice and dramatically improved outcomes. In this review, we will retrace the development of molecular-target drugs and the current therapeutic scenario for patients with BRAF mutated melanoma, from the introduction of BRAF inhibitors as single agents to modern clinical practice. We will also discuss the resistance mechanisms identified so far, and the future therapeutic perspectives in BRAF mutated melanoma., (Copyright © 2020 Tanda, Vanni, Boutros, Andreotti, Bruno, Ghiorzo and Spagnolo.)
- Published
- 2020
- Full Text
- View/download PDF
42. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape.
- Author
-
Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, and Ghiorzo P
- Abstract
The incidence of melanoma, among the most lethal cancers, is widespread and increasing. Metastatic melanoma has a poor prognosis, representing about 90% of skin cancer mortality. The increased knowledge of tumor biology and the greater understanding of the immune system role in the anti-tumor response has allowed us to develop a more rational approach to systemic therapies. The discovery of activating BRAF mutations in half of all melanomas has led to the development of molecularly targeted therapy with BRAF and MEK inhibitors, which dramatically improved outcomes of patients with stage IV BRAF-mutant melanoma. More recently, the results of clinical phase III studies conducted in the adjuvant setting led to the combined administration of BRAF and MEK inhibitors also in patients with resected high-risk melanoma (stage III). Therefore, BRAF mutation testing has become a priority to determine the oncologist's choice and course of therapy. In this review, we will report the molecular biology-based strategies used for BRAF mutation detection with the main advantages and disadvantages of the most commonly used diagnostic strategies. The timing of such molecular assessment in patients with cutaneous melanoma will be discussed, and we will also examine considerations and approaches for accurate and effective BRAF testing., (Copyright © 2020 Vanni, Tanda, Spagnolo, Andreotti, Bruno and Ghiorzo.)
- Published
- 2020
- Full Text
- View/download PDF
43. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: 18 F-FDG PET/CT Study.
- Author
-
Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E, Bongioanni F, Biello F, Dal Bello MG, Barletta G, Massollo M, Vanni I, Piva R, Nieri A, Bauckneht M, Sambuceti G, and Grossi F
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung pathology, Female, Fluorodeoxyglucose F18, Glycolysis, Humans, Image Processing, Computer-Assisted, Lung Neoplasms pathology, Male, Middle Aged, Multimodal Imaging, Neoplasm Metastasis pathology, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung metabolism, DNA, Neoplasm blood, Lung Neoplasms drug therapy, Lung Neoplasms metabolism, Tumor Burden
- Abstract
We aimed to evaluate the relationships between circulating tumor cells (CTCs) or plasma cell-free DNA (cfDNA) on one side and a comprehensive range of
18 F-FDG PET/CT-derived parameters on the other side in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). Methods: From a group of 79 patients included in a trial evaluating the role of pretreatment circulating tumor markers as predictors of prognosis in chemotherapy-naive patients with advanced NSCLC, we recruited all those who underwent18 F-FDG PET/CT for clinical reasons at our institution before inclusion in the trial (and thus just before chemotherapy). For each patient, a peripheral blood sample was collected at baseline for the evaluation of CTCs and cfDNA. CTCs were isolated by size using a filtration-based device and then morphologically identified and enumerated; cfDNA was isolated from plasma and quantified by a quantitative polymerase chain reaction using human telomerase reverse transcriptase. The following18 F-FDG PET/CT-derived parameters were computed: maximum diameter of the primary lesion (T), of the largest lymph node (N), and of the largest metastatic lesion (M); SUVmax ; SUVmean ; size-incorporated SUVmax ; metabolic tumor volume; and total lesion glycolysis. All parameters were independently measured for T, N, and M. The associations among CTCs, cfDNA, and18 F-FDG PET/CT-derived parameters were evaluated by multivariate-analysis. Patients were divided into 2 groups according to the presence of either limited metastatic involvement (M1a or M1b due to extrathoracic lymph nodes only) or disseminated metastatic disease. The presence or absence of metabolically active bone lesions was also recorded for each patient, and patient subgroups were compared. Results: Thirty-seven patients recruited in the trial matched our PET-based criteria (24 men; age, 64.5 ± 8.1 y). SUVmax for the largest metastatic lesion was the only variable independently associated with baseline cfDNA levels ( P = 0.016). Higher levels of cfDNA were detected in the subgroup of patients with metabolically active bone lesions ( P = 0.02), but no difference was highlighted when patients with more limited metastatic disease were compared with patients with disseminated metastatic disease. Conclusion: The correlation of cfDNA levels with tumor metabolism, but not with metabolic tumor volume at regional or distant levels, suggests that cfDNA may better reflect tumor biologic behavior or aggressiveness rather than tumor burden in metastatic NSCLC., (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2017
- Full Text
- View/download PDF
44. Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.
- Author
-
Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Vigani A, Fedeli F, Beer DG, Roncella S, and Grossi F
- Abstract
Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal overall survival (OS) and to date no molecular markers are available to guide patient management. This study aimed to identify a prognostic miRNA signature in MPM patients who did not undergo tumor resection. Whole miRNA profiling using a microarray platform was performed using biopsies on 27 unresected MPM patients with distinct clinical outcome: 15 patients had short survival (OS<12 months) and 12 patients had long survival (OS>36 months). Three prognostic miRNAs (mir-99a, let-7c, and miR-125b) encoded at the same cluster (21q21) were selected for further validation and tested on publicly available miRNA sequencing data from 72 MPM patients with survival data. A risk model was built based on these 3 miRNAs that was validated by quantitative PCR in an independent set of 30 MPM patients. High-risk patients had shorter median OS (7.6 months) as compared with low-risk patients (median not reached). In the multivariate Cox model, a high-risk score was independently associated with shorter OS (HR=3.14; 95% CI, 1.18-8.34; P=0.022). Our study identified that the downregulation of the miR-99a/let-7/miR-125b miRNA cluster predicts poor outcome in unresected MPM., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
- Published
- 2017
- Full Text
- View/download PDF
45. Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
- Author
-
Rijavec E, Genova C, Barletta G, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Vanni I, Boccardo S, Alama A, and Grossi F
- Subjects
- Animals, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Drug Design, Drug Resistance, Neoplasm, Drugs, Investigational pharmacology, Humans, Lung Neoplasms pathology, Molecular Targeted Therapy, Receptors, Fibroblast Growth Factor antagonists & inhibitors, Antineoplastic Agents pharmacology, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Introduction: Fibroblast growth factor receptor (FGFR) due to its central role in regulating cell survival, is a promising target for cancer therapeutics. Dysregulation of the FGFR pathway has been observed in several malignancies, including non-small cell lung cancer (NSCLC) particularly in patients with squamous histology. Areas covered: The aim of this article is to review the most relevant findings of clinical trials investigating drugs targeting FGFR pathway: such as FGFR tyrosine kinase inhibitors (TKIs), FGFR monoclonal antibodies and FGF ligand traps in NSCLC patients. Expert opinion: At present, clinical activity of drugs targeting FGFR in NSCLC is disappointing. Further studies are needed in order to better identify patients who might benefit from these drugs and to clarify the mechanisms of resistance to these compounds.
- Published
- 2017
- Full Text
- View/download PDF
46. New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.
- Author
-
Genova C, Rijavec E, Biello F, Rossi G, Barletta G, Dal Bello MG, Vanni I, Coco S, Alama A, and Grossi F
- Subjects
- Anaplastic Lymphoma Kinase, Drug Resistance, Neoplasm, ErbB Receptors antagonists & inhibitors, Humans, Protein Kinase Inhibitors therapeutic use, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Introduction: Although the achievements in the treatment of advanced non-small cell lung cancer (NSCLC) have been translated in improved disease control, response rate and survival, especially in the case of patients with targetable oncogenic drivers, acquired resistance is common after initial benefit; furthermore, primary resistance can occasionally be observed. Due to its clinical implications, the management of treatment-resistant NSCLC is a top topic of the current research, and many efforts are being put in the study of the mechanisms at the base of resistance and in the development of effective therapeutic countermeasures. Areas covered: This review aims at identifying the most relevant novel chemical therapies designed to overcome resistance in NSCLC, including recently approved agents, as well as compounds in clinical development. Expert opinion: An improved knowledge of the mechanisms causing resistance to treatments in NSCLC translates into effective innovative chemical therapies able to overcome such occurrence, and the paradigms of this progress are represented by novel inhibitors of the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK); however, the study of novel systemic therapies in this setting is challenging, and further efforts in this setting are highly needed.
- Published
- 2017
- Full Text
- View/download PDF
47. Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
- Author
-
Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, and Grossi F
- Subjects
- Antineoplastic Agents therapeutic use, Ephrins therapeutic use, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Mesothelioma drug therapy, Mesothelioma mortality, Mesothelioma, Malignant, Pemetrexed therapeutic use, Pleural Neoplasms drug therapy, Pleural Neoplasms mortality, Prognosis, Ribonucleases therapeutic use, Biomarkers, Tumor genetics, Lung Neoplasms genetics, Mesothelioma genetics, MicroRNAs genetics, Pleural Neoplasms genetics
- Abstract
Malignant Pleural Mesothelioma (MPM) is an aggressive disease characterized by a dismal prognosis, mainly due to late diagnosis. To date, there are very few treatment options available and the refractoriness to the majority of therapeutic strategies, leading to consider MPM a relevant problem in public health. Therefore, the identification of novel prognostic markers and alternative therapeutic strategies remain a top priority. Several efforts have been made in this direction and to date a number of studies have investigated the role of microRNA as biomarkers in MPM, identifying the potential prognostic role of miR-29c* and miR-31. Very recently, the first microRNA signature able to discriminate poor or and good prognosis of MPM patients underwent surgery has been published. Very interestingly, several microRNA such as miR-1, miR-16, and miR-34b/c have been identified as potential therapeutic agents. Indeed, the forced expression of these microRNA resulted in anti-tumor effects both in vitro and in vivo. Besides, the introduction of microRNA mimic, some agents such as EphrinA1 and Onconase, seemed to exert anti-tumor effects through specific microRNA. Moreover, microRNA have also been reported to play a role in chemoresistance enhancing the sensitivity to specific drug such as pemetrexed. In this review the most relevant and updated data about the role of microRNA as prognostic markers and therapeutic agents in MPM will be presented, opening new avenues towards improved management of this aggressive disease.
- Published
- 2016
- Full Text
- View/download PDF
48. HLA-B and HLA-C Supratyping by Pyrosequencing®.
- Author
-
Vanni I, Ugolotti E, Larghero P, and Biassoni R
- Subjects
- Alleles, Genetic Loci genetics, Genomics, Humans, Polymerase Chain Reaction, Polymorphism, Single Nucleotide, HLA Antigens genetics, HLA Antigens immunology, HLA-C Antigens genetics, HLA-C Antigens immunology, Histocompatibility Testing methods, Sequence Analysis, DNA methods
- Abstract
Usually, HLA typing has been performed either by serology-based typing incubating a panel of known anti-HLA antibodies with viable lymphocytes of unknown HLA type or by molecular typing including medium-resolution HLA typing by Sequence Specific Oligonucleotide Probes (SSOP) or high-resolution HLA typing by Sequence Based Typing (SBT). Traditionally, HLA antigens have been defined using serological techniques, but these methods have several disadvantages, such as low resolution, the requirement for viable cells, and cell surface expression of HLA molecules. HLA type screening methods are categorized as low, medium, and high resolution, and only sequencing-based typing methods provide the highest resolution and are considered the gold standard for HLA typing.Among the HLA SBT based-methods, the Pyrosequencing(®) technique is an extremely versatile and accurate real-time sequencing technique with some advantages compared to classic Sanger method.Here, we describe a quick and inexpensive method that allows through the use of Pyrosequencing subtyping of HLA class I molecules, into HLA-Bw6, -Bw4 I80, or -Bw4 T80 and HLA-C1, or -C2 groups. In particular, this analysis is focused on the amino acids around residue 80. This method demonstrated good sensitivity, specificity, and reproducibility. Using a quantitative allele acquisition mode, the method provides accurate sequence information required for the definition of heterozygous and/or homozygous samples.
- Published
- 2015
- Full Text
- View/download PDF
49. Belagenpumatucel-L for the treatment of non-small cell lung cancer.
- Author
-
Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, and Grossi F
- Subjects
- Antigens, Neoplasm immunology, Cancer Vaccines immunology, Carcinoma, Non-Small-Cell Lung immunology, Carcinoma, Non-Small-Cell Lung pathology, Clinical Trials as Topic, Humans, Immunotherapy, Lung Neoplasms immunology, Lung Neoplasms pathology, Transforming Growth Factor beta2 antagonists & inhibitors, Transforming Growth Factor beta2 genetics, Cancer Vaccines therapeutic use, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms therapy
- Abstract
Introduction: Immunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-β2 gene., Areas Covered: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients., Expert Opinion: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.
- Published
- 2015
- Full Text
- View/download PDF
50. Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.
- Author
-
Coco S, Truini A, Vanni I, Dal Bello MG, Alama A, Rijavec E, Genova C, Barletta G, Sini C, Burrafato G, Biello F, Boccardo F, and Grossi F
- Subjects
- Drug Resistance, Neoplasm, Humans, Mutation, Precision Medicine, Carcinoma, Non-Small-Cell Lung genetics, DNA Mutational Analysis methods, High-Throughput Nucleotide Sequencing methods, Lung Neoplasms genetics
- Abstract
Non-small cell lung cancer (NSCLC) is one of the most common causes of cancer-related death worldwide. Based on the patient's stage of disease, treatment options include surgery, radiotherapy, and chemotherapy. Although chemotherapy remains the main therapeutic approach for advanced NSCLC, targeted therapy represents a good chance of treatment for this subgroup of patients. Currently this approach is based on previous evaluation of clinically relevant mutations and the Sanger sequencing is the main approach to assign mutational status and to guide the appropriate treatment; however this tool is characterized by a low sensitivity. Recently, the advent of next-generation sequencing (NGS) has dramatically revolutionized the molecular knowledge of cancer by increasing the feasibility and possibility to sequence DNA ranging from large scale studies to targeted regions. This review reports an overview of different applications of the NGS as novel approach to study NSCLC, thereby providing information about mutational spectrum of this cancer in order to identify novel targetable mutations and to predict the emergence of drug resistance. All studies demonstrated several advantages of this approach over the traditional tools. In particular the NGS was also able to reveal mutations in low percentage, and to screen the mutational status of different critical samples such as biopsies, cytological samples and circulating plasma DNA, offering innovative diagnostic opportunities. Despite several problems have to be overcome toward the personalized therapy, the NGS represents a highly attractive system to identify mutations improving the outcome of patients with this deadly disease.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.